News from prolor biotech, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 29, 2013, 12:22 ET

OPKO Completes Acquisition Of PROLOR Biotech

 OPKO Health, Inc. (NYSE: OPK) ("OPKO") and PROLOR Biotech, Inc. (NYSE MKT: PBTH) ("PROLOR") jointly announced today the completion of the...

Jul 03, 2013, 07:30 ET

PROLOR Biotech to Present Positive Results From Preclinical Studies of Long-Acting Clotting Factor VIIa-CTP at ISTH 2013

 PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new results from preclinical studies of its long-acting...

Jun 13, 2013, 07:30 ET

PROLOR Biotech To Present New Data On Its Long-Acting Human Growth Hormone And Long-Acting Oxyntomodulin At ENDO 2013

 PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting human growth hormone...

Jun 04, 2013, 07:30 ET

PROLOR Biotech Initiates Pivotal Phase III Trial Of Its Longer-Acting Version Of Human Growth Hormone

PROLOR Biotech, Inc. (NYSE Mkt: PBTH), a company developing next-generation biobetter therapeutic proteins, today announced the initiation of a...

May 31, 2013, 07:39 ET

PROLOR Biotech To Present At Jefferies 2013 Global Healthcare Conference

 PROLOR Biotech, Inc. (NYSE MKT: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced...

Apr 24, 2013, 02:00 ET

OPKO Health To Acquire PROLOR Biotech

OPKO Health, Inc. (NYSE: OPK) and PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that the companies have signed a definitive merger...

Apr 08, 2013, 07:30 ET

PROLOR Biotech Receives Notice of Allowance For New U.S. Patent Covering Long-Acting Coagulation Factors VII and IX

 PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that it received a notice of allowance from the U.S. Patent and Trademark Office for a...

Mar 05, 2013, 07:30 ET

PROLOR Biotech Receives Notice of Allowance for New U.S. Patent Covering Methods for Decreasing Body Fat with hGH-CTP

PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO)...

Feb 13, 2013, 07:30 ET

PROLOR Biotech's Longer-acting Human Growth Hormone Receives Orphan Drug Designation in Europe

 PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that the European Commission and the European Medicines Agency (EMA) have granted orphan...

Feb 06, 2013, 07:30 ET

PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference

 PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting clotting factor VIIa (Factor...

Jan 07, 2013, 07:30 ET

PROLOR Biotech Receives Notice of Allowance for New U.S. Patent Covering Broad Applications of its CTP Platform for Long Acting Therapeutic Proteins

PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that it received a notice of allowance from the U.S. Patent and Trademark Office for a patent...

Dec 10, 2012, 07:30 ET

PROLOR Biotech To Present At Oppenheimer 23rd Annual Healthcare Conference

 PROLOR Biotech, Inc. (NYSE MKT:PBTH) today announced that company management will give a corporate presentation at the Oppenheimer 23rd Annual...

Dec 07, 2012, 07:30 ET

PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting

 PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present preclinical data on its long-acting clotting Factor VIIa...

Nov 13, 2012, 07:30 ET

New Patent Covering PROLOR's Reversible-Pegylation Platform Technology is Allowed by U.S. Patent Office

 PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that the U.S. Patent and Trademark Office issued a notice of allowance for a patent...

Oct 18, 2012, 07:30 ET

PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At Congress Of The GRS And IGF Society

 PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that researchers will present data from the company's Phase II trial of its long-acting...

Oct 16, 2012, 07:30 ET

PROLOR Biotech Announces Positive Results From Preclinical Toxicology Study Of Its Reversible-Pegylation Platform Technology

 PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced positive results from a preclinical toxicology study designed to assess the safety and...

Oct 03, 2012, 07:30 ET

PROLOR Biotech Receives Notice of Allowance for New U.S. Patent for Its Long-Acting Human Growth Hormone

 PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office...

Sep 21, 2012, 07:30 ET

PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Pediatric Endocrinology Meeting

 PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that data from the company's Phase II trial of hGH-CTP, its long acting human growth...

Sep 13, 2012, 07:40 ET

PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting

 PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that researchers at ENEA 2012, the 15th Annual Congress of the European NeuroEndocrine...

Jul 10, 2012, 07:30 ET

PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress

PROLOR Biotech, Inc. (NYSE MKT: PBTH), announced that the company will present data today on its long-acting clotting factors for the treatment...